# Hepatocellular Carcinoma Treatment and BCLC Staging

> Hepatocellular carcinoma treatment for NEET-PG Medicine: BCLC stage and Child-Pugh class decide resection, ablation, TACE, systemic therapy or transplant.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/hepatocellular-carcinoma-treatment-bclc
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-08
- Last updated: 2026-10-08
- Reference basis: Harrison's Principles of Internal Medicine; EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma; Sleisenger and Fordtran's Gastrointestinal and Liver Disease
- How to cite: "Hepatocellular Carcinoma Treatment and BCLC Staging", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/hepatocellular-carcinoma-treatment-bclc

## Direct answer

Hepatocellular carcinoma treatment is chosen by the Barcelona Clinic Liver Cancer staging system, which weighs tumour burden, vascular invasion, Child-Pugh liver reserve and performance status together. Very early and early tumours in patients with preserved liver function are treated with curative intent by resection, ablation or transplant. Liver reserve often decides the choice more than tumour size.

## What you must remember

- **Staging inputs:** BCLC combines tumour number and size, macrovascular invasion or extrahepatic spread, Child-Pugh class and ECOG performance status.
- **Very early and early stages:** a single nodule up to 2 cm (stage 0), or a single tumour of any size or up to three nodules of 3 cm or less (stage A), with preserved liver function.
- **Stage B:** multinodular disease without vascular invasion in Child-Pugh A or B patients is the classic indication for TACE.
- **Stage C:** portal vein invasion, extrahepatic spread or ECOG 1 to 2 points to systemic therapy, with atezolizumab plus bevacizumab and sorafenib as established first-line options.
- **Stage D:** Child-Pugh C (not a transplant candidate) or ECOG 3 to 4 means terminal disease, managed with best supportive care.
- **Milan criteria:** a single tumour up to 5 cm, or up to three nodules none above 3 cm, without vascular invasion or extrahepatic disease, defines transplant eligibility.
- **Ablation range:** radiofrequency or microwave ablation suits lesions up to about 3 cm, while resection is favoured in Child-Pugh A patients without portal hypertension.

## Walking a single nodule to a plan

Consider a 58-year-old man with hepatitis B cirrhosis, Child-Pugh B7 and an ECOG score of 0, whose ultrasound shows a single 4 cm lesion in segment VII.

| BCLC stage | Criteria | Usual treatment |
|---|---|---|
| 0 and A | Single nodule up to 2 cm (0), or single tumour of any size or up to three nodules of 3 cm or less (A), with preserved liver function | Resection, ablation or transplant |
| B | Multinodular, no vascular invasion, Child-Pugh A or B | TACE |
| C | Portal vein invasion, extrahepatic spread or ECOG 1 to 2 | Systemic therapy, such as atezolizumab plus bevacizumab |
| D | Child-Pugh C or ECOG 3 to 4 | Best supportive care |

Multiphase contrast CT confirms arterial hyperenhancement with washout, so a biopsy is not needed. BCLC places him at stage A because a single tumour of any size qualifies, but his Child-Pugh B status makes resection hazardous, and a low platelet count, if present, would hint at portal hypertension.

He meets the Milan criteria, so transplant is the first option at a centre with access to listing, with ablation or TACE as the alternative if transplant is not feasible.

Vary the facts: three nodules larger than 3 cm make stage B and TACE, while portal vein thrombus makes stage C.

## Where the examiner tries to catch you

Two classifications are blurred.

- **Trap:** using Milan criteria and BCLC interchangeably. — **Correct:** Milan decides transplant eligibility, whereas BCLC is a staging and treatment-allocation system, so a patient inside Milan can still fall into a later stage.
- **Trap:** choosing TACE when the portal vein is involved. — **Correct:** tumour thrombus in the portal vein points to stage C and systemic therapy, not TACE.
- **Trap:** insisting on biopsy for every lesion. — **Correct:** in cirrhosis, a lesion over 1 cm with typical multiphase imaging is diagnostic, and biopsy is kept for atypical lesions or non-cirrhotic livers.

## Frequently asked questions

### Which BCLC stage is treated with transarterial chemoembolisation?

Transarterial chemoembolisation is the standard treatment for BCLC stage B hepatocellular carcinoma, meaning multinodular tumours without vascular invasion or extrahepatic spread in Child-Pugh A or B patients with good performance status. TACE is palliative in intent rather than curative, and it is generally avoided in Child-Pugh C disease.

### What are the Milan criteria for liver transplant in hepatocellular carcinoma?

The Milan criteria allow transplant for a single hepatocellular carcinoma up to 5 cm, or up to three nodules none larger than 3 cm, with no macrovascular invasion and no extrahepatic spread.

### When is radiofrequency ablation preferred over surgical resection?

Radiofrequency ablation is preferred for small hepatocellular carcinomas, usually up to about 3 cm, when the lesion sits where surgery is risky or the liver function is marginal. Resection remains the first choice for well-compensated patients with a solitary tumour and no portal hypertension, because it gives a more reliable margin for larger lesions.

### Which systemic therapy is used first line for advanced hepatocellular carcinoma?

Atezolizumab combined with bevacizumab is a standard first-line systemic option for advanced hepatocellular carcinoma in patients with preserved liver function, while sorafenib and lenvatinib remain established alternatives. Recent variceal bleeding argues against bevacizumab, so the choice also depends on comorbidity.

### Can hepatocellular carcinoma be diagnosed without a biopsy?

In a cirrhotic liver, hepatocellular carcinoma can be diagnosed without a biopsy when a nodule larger than 1 cm shows arterial-phase hyperenhancement with washout on multiphase CT or MRI, the pattern reported as LI-RADS 5. Biopsy is reserved for atypical lesions and for livers without cirrhosis.